What is it about?
Several dual drug therapies have protective effects on the progression of chronic kidney disease but whether triple therapy is superior is unknown. Our preclinical study proves that triple therapy is by far more effective in prolonging kidney lifespan.
Featured Image
Read the Original
This page is a summary of: Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice, Journal of the American Society of Nephrology, July 2023, Wolters Kluwer Health,
DOI: 10.1681/asn.0000000000000186.
You can read the full text:
Contributors
The following have contributed to this page
